Oraya Therapeutics' IRay® Radiotherapy System Wins Silver at 2015 Medical Design Excellence Awards

NEWARK, Calif., June 16, 2015 – Oraya Therapeutics Inc. and Bridge Design announced today that the Oraya IRay® Radiotherapy System has won the Silver award in the radiological and electromechanical devices category of the 18th Annual Medical Design Excellence Awards (MDEA). The winners were announced at a ceremony in New York City at the Jacob Javits Center in conjunction with the MD&M East event.

The MDEA is the medtech industry's premier design competition committed to searching worldwide for the highest caliber finished medical devices, products, systems, or packaging available on the market. The awards program celebrates the achievements of the medical device manufacturers, their suppliers, and the many people behind the scenes – engineers, scientists, designers, and clinicians – who are responsible for the cutting-edge products that are savings lives; improving patient healthcare; and transforming medtech – one innovation at a time.

The 2015 MDEA Juror Panel selected 45 exceptional finalists in 10 medical technology product categories.  Products were judged based on design and engineering innovation; function and user-related innovation; patient benefits; business benefits; and overall benefit to the healthcare system.

"We, alongside our partner Bridge Design, are honored to be recognized with this prestigious award," said Jim Taylor, president and CEO of Oraya Therapeutics. "Our goal in designing and developing the IRay system was to offer ophthalmologists and their patients an innovative, comfortable and non-invasive treatment option for wet AMD. We believe that physician ease-of-use and patient comfort have played a significant role in the rapid adoption of Oraya Therapy in Europe and its continued integration into standard clinical care."

The IRay Radiotherapy System delivers low-voltage X-rays for the treatment of wet age-related macular degeneration (AMD), the leading cause of blindness in those over 65 in the industrialized world. The IRay system's relatively small footprint is designed for installation in a clinic or hospital, without the need for added room shielding, and to be easy to operate. The key proprietary elements of the system consist of a low-energy x-ray tube, a self-contained automated beam positioning system, Oraya Therapy software, the I-Guide™ eye stabilization device and an eye tracking system. Combining these elements into a product that would be patient friendly as well as providing reliability and efficiency with patient workflow was critical.

Bridge Design worked in close collaboration with Oraya to design and engineer the IRay system from conception to commercialization. Extensive ergonomic studies were undertaken to gain a clear understanding of physicians' and patients' needs, and to inform the development of the product for an international market. Streamlined, easy operator steps that could reduce procedure time and increase overall patient comfort were also vital to the design.

"The success of any innovative product in the start-up medical world is a combination of the foresight of the founders, the effectiveness of their core technology and the people they pick to help make it a reality," says Bridge Design's Principal and Founder Bill Evans. "We are honored to have been chosen as Oraya's design partner and glad that our contribution to the usability and customer appeal has helped Oraya achieve rapid adoption. Oraya brought us into their fold, integrating us with their technical and marketing teams. From this teamwork comes the product you see. It is rewarding for our designers to be involved in such vision-maintaining therapy and we wish Oraya well as they expand into new treatment sites."

Oraya Therapy is available at 11 sites in three countries including the United Kingdom, Germany and Switzerland, and additional sites are in the active planning stages. The IRay system is CE marked in Europe. In the U.S., the IRay System is an investigational device and is not available for sale.

###

About the MDEA Awards and Program

Entries are judged by an impartial panel of medtech experts.  Unlike other design competitions, the MDEA jury is comprised of a balance of practicing doctors, nurses, and technicians alongside industrial designers, engineers, manufacturers, and human factors experts.  The Medical Design Excellence Awards are presented by UBM Canon, the global advanced manufacturing and medtech authority, and by Medical Device and Diagnostic Industry (MD+DI). Visit www.MDEAwards.com for more information. 

About Oraya Therapeutics

Oraya Therapeutics, Inc. is a privately held company developing innovative and non-invasive therapies for diseases of the eye. The company was founded in 2007. Its investors include Essex Woodlands Health Ventures, Domain Associates, Scale Venture Partners, and Carl Zeiss Meditec AG. More information about Oraya Therapeutics can be found at www.orayainc.com.

About Bridge Design

Bridge Design, based in San Francisco, has focused for more than two decades on award-winning design of medical and life sciences products - digital as well as physical. Clients range from Fortune 500 to startups, including device manufacturers, pharmaceutical, life science firms, payers and providers, as well as companies in consumer health and wellness. More information about Bridge can be found at bridgedesign.com.

Carrie Fung

Assistant Account Executive | Racepoint Global for Oraya Therapeutics

T: +1 415 694 6729 | C: +1 510 967 3152

[email protected]

@carriegfung | LinkedIn

Connect with us:

Facebook | Twitter | LinkedIn

 

 

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.